HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients

AIDS

Volumn 16, Issue 3, 2002, Pages 387-396

  Falloon, Judith ^a   Ait Khaled, Mounir ^a   Thomas, Deborah A ^a   Brosgart, Carol L ^a   Eron Jr , Joseph J ^a   Feinberg, Judith ^a   Flanigan, Timothy P ^a   Hammer, Scott M ^a   Kraus, Peter W ^a   Murphy, Robert ^a   Torres, Ramon ^a   Masur, Henry ^a   Manion, D J ^a   Rogers, M ^a   Wolfram, J ^a   Amphlett, G E ^a   Rakik, A ^a   Tisdale, M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antiretroviral therapy; Predictors; Rescue regimen; Resistance

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CORRELATION FUNCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED STATES; VIRAL GENETICS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CARBAMATES; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OXAZINES; PHENOTYPE; RETROSPECTIVE STUDIES; RNA, VIRAL; SAFETY; SULFONAMIDES; TREATMENT FAILURE;

EID: 0037083807     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200202150-00010     Document Type: Article

References (33)

1. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
2. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virological failure and adverse drug reactions
3. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA panel
4. Mutations in retroviral genes associated with drug resistance: 1999-2000 Update
5. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
6. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phenotypic drug susceptibility with virological outcome
7. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
8. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virological failure on indinavir: AIDS clinical trials group study 359
9. Randomized trial of abacavir (ABC) and nelfinavir (NFV) in combination with efavirenz (EFV) and adefovir dipivoxil (ADV) as salvage therapy in patients with virological failure receiving indinavir (IDV)
10. Phenotypic testing predicts virological response in successive protease inhibitor-based regimens
11. Baseline prevalence of mutations linked to NNRTI resistance in patients enrolled in clinical studies of efavirenz
12. New insights into genetic mechanisms of HIV drug resistance
13. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples
14. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts outcome of therapy
15. Baseline HIV drug resistance profile predicts response to ritonavir- saquinavir protease inhibitor therapy in a community setting
16. HIV-1 genotypic resistance patterns predict response to saquinavir- ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
17. Impact of drug resistance mutations on virological response to salvage therapy. Swiss HIV cohort study
18. Phenotypic HIV resistance in vitro correlates with viral load response to abacavir (1592, ABC) in vivo
19. Phenotypic drug susceptibility testing predicts long-term virological suppression better than treatment history in patients with human immunodeficiency virus infection
20. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333
21. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
22. Phenotypic resistance testing significantly improves response to therapy: A randomized trial (VIRA3001)
23. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
24. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt study
25. The addition of a second protease inhibitor eliminates amprenavir-efavirenz drug interactions and increases plasma amprenavir concentrations
26. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection
27. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
28. Tolerability profile of amprenavir (APV,141W94) in combination with various NRTIs
29. Abacavir safety and tolerability: Experience from over 25,000 adults and children
30. Hypersensitivity reactions during therapy with abacavir: Analysis of 636 cases for clinical presentation and risk factors
31. Randomized trial of abacavir (ABC) in combination with indinavir (IDV) and efavirenz (EFV) in HIV-infected patients (pts) with nucleoside analog experience (NRTI exp)
32. Durable activity of Ziagen (abacavir, 1592, ABC) combined with protease inhibitors (PI) in antiretroviral therapy naive subjects